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Objectives: Acinetobacter baumannii is an emerging opportunistic nosocomial
pathogen. Two factors that may enhance persistence in healthcare settings are
antimicrobial resistance and biofilm-forming ability. The aim of this work was to determine
whether A. baumannii isolates that persist in healthcare settings (endemic), can be
differentiated from sporadic isolates based upon their ability to resist antibiotics and their
biofilm-forming capability.
Methods: Two hundred and ninety A. baumannii isolates were isolated over 17 months
in the Detroit Medical Center (DMC). The isolates were genotyped using repetitive
extragenic palindromic-PCR (REP-PCR). REP-types appearing greater than 10 times
during active surveillance were considered endemic. The in vitro biofilm-forming ability
and antibiotic resistance profile of each isolate were evaluated. Isolates were tested for
the presence of two genetic markers—one implicated in biofilm formation (bap) and the
other in antibiotic resistance (blaOXA-23).
Results: Of the 290 isolates evaluated, 84% carried bap and 36% carried blaOXA-23. Five
unique REP-PCR banding-types were detected >10 times (endemic) and constituted
58% of the 290 isolates. These five endemic REP-PCR types were 5.1 times more likely
than sporadic isolates to carry both bap and blaOXA-23. Furthermore, endemic isolates
were resistant to 3 more antibiotic classes, on average, than sporadic isolates and four of
the five endemic REP-PCR types formed denser biofilms in vitro than sporadic isolates.
Conclusions: Endemic A. baumannii isolates are more likely than sporadic isolates to
possess factors that increase virulence and enhance survival within a large healthcare
system.
Keywords: molecular epidemiology, REP-PCR, bap, OXA-23, antibiotic resistance, biofilms
Introduction
Acinetobacter baumannii is a Gram-negative coccobacillary bacterium that is environmentally
ubiquitous. It is capable of causing severe nosocomial infections, especially among patients who
are immunocompromised (due to underlying medical conditions or age), have medical devices,
or are frequently exposed to antibiotics (Bergogne-Berezin, 2001; Maragakis and Perl, 2008).
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A. baumannii is intrinsically tolerant to many antimicrobials
and is capable of rapidly acquiring antibiotic resistances. Conse-
quently, it is not unusual to observe considerable and unexpected
increases in the number of resistant isolates within a healthcare
facility over short periods of time. For example, within tertiary
care facilities in Greece, there were no reported imipenem-
resistant A. baumannii before 1996, but by 2006 91% of A. bau-
mannii that were isolated were imipenem-resistant (Falagas et al.,
2007). A similar trend was observed at the Detroit Medical Cen-
ter (DMC) in Michigan where imipenem-resistant A. baumannii
isolates increased from 1% to 58% between 2003 and 2008 (Reddy
et al., 2010).
Given the volume and spectrum of antimicrobials used in
healthcare settings, sometimes to an excessive and inappropriate
degree (Craig et al., 1978; Huttner et al., 2013), resistant clonal
pathogens can emerge and circulate globally (Butaye et al., 2006;
Samuelsen et al., 2011; Martins et al., 2015). Knowledge of the
biology behind recirculation and persistence may aid in future
prevention and/or treatment strategies. For instance, multidrug
eﬄux pumps that enable the survival of bacteria in the face of
antimicrobial challenge have also been suggested to directly influ-
ence colonization and persistence (Piddock, 2006). Only a few
small-scale studies have investigated the association of antibiotic
resistance to the circulation and/or persistence of PCR-genotyped
A. baumannii isolates in a healthcare system. In Spain, PCR fin-
gerprinting of 29 imipenem-resistant A. baumannii isolates col-
lected at a large hospital in Madrid showed that they belonged
to a single circulating clone (Bou et al., 2000). A similar study
conducted in China found that 24 multi-drug resistant isolates
collected from various sources in Sichuan Province had identi-
cal REP-PCR patterns (Luo et al., 2011). A study of 23 epidemic
A. baumannii isolates compared to 23 sporadic isolates collected
from 9 European countries demonstrated epidemic isolates were
significantly more resistant than sporadic isolates (Koeleman
et al., 2001).
An important virulence biomarker in A. baumannii is the
blaOXA-23 gene, which codes for the carbapenemase OXA-23,
one of five Ambler class D β-lactamases identified in A. bau-
mannii (Opazo et al., 2012). Outbreaks of OXA-23 producing
A. baumannii have been characterized worldwide and associ-
ated with multi-drug resistance (Coelho et al., 2006). Although
OXA-23 production directly confers resistance to carbapenems,
possessing the gene is often a marker for other resistances,
including cephalosporins, beta-lactams, fluoroquinolones, and
aminoglycosides (Dalla-Costa et al., 2003; Girlich et al., 2010).
These drug classes are normally used to classify multi-drug
resistant A. baumannii (Falagas et al., 2006). OXA-23 produc-
ers were first isolated in the United States in 2008, from a
multidrug resistant A. baumannii outbreak in Detroit (Dou-
glass et al., 2008). However, it is unknown whether the pres-
ence of the blaOXA-23 gene in A. baumannii is associated with
persistence.
Biofilms enhance the persistence of microorganisms within
adverse environments, serve as a reservoir for dissemination of
microorganisms in favorable conditions, and act as a nidus for the
exchange of antimicrobial resistance genes (Hall-Stoodley and
Stoodley, 2005). Biofilms are surface-associated communities of
aggregated microorganisms that produce large amounts of extra-
cellular polymeric substances (Donlan and Costerton, 2002).
Increasing evidence suggests that the ability of A. baumannii
to form biofilms enhances antibiotic resistance/tolerance and
also promotes persistence in hospital settings (Rao et al., 2008;
Rodriguez-Bano et al., 2008). In particular, the biofilm associ-
ated protein (bap) gene present on the chromosome in some (but
notably not all) strains of A. baumannii codes for cell-surface-
associated Bap that is responsible for the development of three-
dimensional biofilm towers and channels on abiotic and biotic
surfaces (Brossard and Campagnari, 2012). Transposon mutage-
nesis of the coding region of bap has been shown to reduce the
volume and thickness ofA. baumannii 14 h biofilms bymore than
2-fold (Loehfelm et al., 2008).We are aware of only one study that
examined the prevalence of the bap gene in clinical A. bauman-
nii isolates. In a study focusing on clinical A. baumannii isolated
over a span of 10 years from Royal Brisbane andWomen’s hospi-
tal, the bap gene was present in 22 of 24 isolates that were tested
(92%) (Goh et al., 2013).
There has not been a large-scale assessment to determine
whether endemic healthcare isolates are more likely than spo-
radic isolates to possess a greater number of antibiotic resis-
tances and enhanced biofilm-forming abilities. For the purposes
of this study, identical repetitive extragenic palindromic PCR
(REP-PCR) types shared by at least 10 isolates across our study
population were considered endemic. The aim of our study was
to analyze the prevalence of antibiotic resistance, quantify biofilm
formation, and probe for the presence of bap and blaOXA-23
among a collection of A. baumannii isolates at a large healthcare
system in Southeast Michigan. Ultimately, through laboratory-
based approaches using diagnostic tests, molecular analyses, and
microscopic imaging, we show data that indicates antimicrobial
resistance and biofilm formation are linked to circulation and
persistence of A. baumannii.
Materials and Methods
Surveillance Site
The DMC is a large tertiary referral healthcare system that ser-
vices Southeast Michigan. It consists of 8 hospitals and over
2000 inpatient beds. The central microbiology lab processes
over 500,000 specimens annually. From January 2010 to May
2011, a total of 426 clinical A. baumannii isolates were col-
lected from DMC hospitals and facilities. 136 of these iso-
lates were cultured from patients residing at a nursing home
that is physically located within DMC. Since our focus is on
nosocomial spread, we excluded these isolates. Thus, the final
sample size was 290 isolates collected from 7 hospitals that com-
prise the DMC. Collection of the isolates and their examination
was approved by the appropriate Institutional Review Boards
at the DMC [059112MP2E] and the University of Michigan
[HUM00064166].
Strains and Culture Conditions
A. baumannii isolates were transferred to the University of
Michigan School of Public Health using stab cultures. The stab
culture vials were plated onto Bacto™ R2A agar (Reasoner and
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Geldreich, 1985) and checked for purity by examining colony
color and morphology. A colony from each isolate was then
picked and inoculated into a set of 1.5mL cryogenic vials con-
taining R2A broth. The vials were incubated overnight and a
frozen working stock (−80◦C) was prepared by adding glycerol
to a total concentration of 25%. All subsequent re-culturing was
performed by sub-culturing a loop-full of the working stock on
to R2A agar, minimizing repeated culturing steps. Colonies that
were developed from overnight incubation at 37◦C were used for
comparative studies.
DNA-Template Preparation
From a fresh overnight isolation plate on R2A agar, 4–5 colonies
were removed using a sterile toothpick and inoculated into a
0.2mL PCR tube containing nuclease free water. The tubes were
vortexed for approximately 30 s to suspend the cells. After sus-
pension, the tubes were boiled at 95◦C for 15min in a Bio-
Rad S1000™ Thermal Cycler (Hercules, CA) to lyse the cells
as described by Snelling et al. (1996) After boiling, the samples
were frozen in −80◦C freezers during PCR reagent preparation
to enhance lysis of any remaining intact cells.
Repetitive Element Palindromic (REP)-PCR
Genotyping
REP typing was performed using previously published primer
sets (Vila et al., 1996). The oligonucleotide primers were prepared
by Invitrogen (Carlsbad, CA). Amplification reactions were per-
formed using Promega’s GoTaq R© Green Master Mix (Madison,
WI). Each reaction contained 12.5µL of GoTaq R© Green, 2.5µL
of template, 2.5µL of 1µM primer mixture of both forward and
reverse primers, 2.5µL of dimethyl sulfoxide as a stabilizer for
GC-rich regions of A. baumannii (Ralser et al., 2006), and 5µL
of nuclease-free water. The optimized PCR protocol was as fol-
lows: an initial denaturation step of 95◦C for 3min followed by
30 cycles of denaturation at 90◦C for 30 s, annealing at 40◦C for
1min, and extension at 65◦C for 8min. A final extension time of
16min at 65◦C was included at the end of the cycle. Amplified
products were imaged under UV (300 nm wavelength) and dig-
ital images captured. A 1Kb + ladder was used every 4 lanes to
ensure comparability between lanes. Phylogenetic trees were con-
structed using PyElph version 1.4 (Pavel and Vasile, 2012). Lanes
and bands were manually detected and compared to a 1 kb plus
ladder lane. The neighbor joining method was used to visually
display REP-clusters.
Definitions of Sporadic and Endemic
We defined endemicA. baumannii as isolates with identical REP-
PCR fingerprinting present in counts of greater than 10 across
our study population. All other isolates were considered sporadic.
Detection of bap and blaOXA-23-Like Genes
For blaOXA-23 we used primer sets as described by Jeon et al.
(2005) with modified PCR conditions. The primer set used for
bap were designed using BLAST by Christine Greene (Univer-
sity of Michigan Department of Environmental Health Sciences).
These were bap-F 5′-AGTTAAAGAAGGGCAAGAAG-3′ (for-
ward) and bap-R 5′-GGAGCACCACCTAACTGA-3′ (reverse).
The PCR protocols for amplication of blaOXA-23 and bap were
identical asides from the annealing temperature. The protocols
are as follows: 95◦C for 1min as an initial denaturation step fol-
lowed by 30 cycles of 95◦C for 30 s, 49◦C/45◦C for 30 s, and 72◦C
for 1min. A final elongation step at 72◦C for 5min concluded the
protocol. The annealing temperature was optimized at 49◦C for
blaOXA-23 and 45
◦C for bap. Products from the reaction were run
on 1% agarose gels at 100V and visualized under UV (300 nm
wavelength) to determine presence or absence of gene.
Antibiotic Susceptibility Testing
Antibiotic susceptibility testing was conducted at the clinical
laboratory at the Henry Ford Hospital using the broth micro-
dilution technique MicroScan (Siemens, Erlangen, Germany).
The panel also positively identified the species as A. baumannii.
Resistant MIC breakpoints were used according to CLSI stan-
dards with “1” indicating full resistance (CLSI, 2011). Interme-
diately susceptible isolates were considered susceptible. There
were 16 antibiotics (shown in Table 2) in the panel for which
there exist 2011 CLSI guidelines. For Tigecycline we used the
2011 BSAC guidelines to determine resistant breakpoints (BSAC,
2011).
Biofilm Quantification
Biofilm quantificationwas performed on both sterile polystyrene-
bottomed and glass-bottomed 96-well plates using a modified
crystal violet assay method (O’Toole and Kolter, 1998). Each well
was filled with 100µL of R2A broth and subsequently inoculated
with an isolate from the study sample. Isolates were inoculated
in triplicate and incubated at 37◦C for 18 h. Subsequently, the
excess culture media was aspirated and the biofilms were stained
with 50µL of crystal violet. After 15min of staining, the wells
were washed 3×with deionized water for 10min eachwash. After
the last wash, the plates were air dried for 30min and 50µL of
95% ethanol was added to each well and gently agitated to bring
any remaining crystal violet into solution. The O.D. at 560 nm
for each triplicate was recorded in a Wallac Victor 3 multilabel
plate reader (Perkin-Elmer, Waltham, MA) and the average value
calculated.
Biofilm Imaging
Three representative isolates were chosen for imaging. They
included a bap alone isolate, a bap + blaOXA-23 positive isolate,
and a bap + blaOXA-23 negative isolate (note, no blaOXA-23 alone
were detected in our study) of A. baumannii (isolates DMC0256,
DMC0420, andDMC0551, respectively). Amodifiedmethod that
was developed by Rao and colleagues was used (Rao et al., 2011).
Biofilms were developed overnight at 37◦C in polystyrene 4-well
chamber slide system (Lab-Tek, Naperville, IL) containing 2mL
of R2A media per well. The media was aspirated from each well
and stained with prepared 10µM solution of Syto-9 stain (Invit-
rogen, Carlsbad, CA) for 30min. Subsequently, the biofilms were
washed with PBS (pH 7.4) three times. A Leica SPE (Leica, Buf-
falo Grove, IL) confocal laser scanning microscope (CLSM) was
used to examine the stained biofilms. Syto-9 stained biofilms
were excited with a 488 nm solid-state laser and fluorescence
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was captured between 500–550 nM with a 40 × 1.25 NA objec-
tive lens. Gain and offset were calibrated using the Leica look-
up-table and kept constant for experiments. Following biofilm
imaging, biofilmswere rendered using IMARIS version 7.3.1 (Bit-
plane, Zurich, Switzerland) imaging software. Captured render-
ings were assembled in CORELDRAW v. X4 (Corel, Mountain
View, CA).
Definition of Multi-Drug Resistance (MDR) and
Pan Drug Resistance (PDR)
The definition of MDR and PDR A. baumannii is not fixed
and it varies by researcher in numerous published works (Man-
chanda et al., 2010). Here, we defined MDR A. baumannii
as having resistance to any combination of 3 or more of the
five drug classes commonly used to treat Gram negative infec-
tions: cephalosporins, carbapenems, β-lactam and β-lactamase
inhibitor combinations, fluoroquinolones, and aminoglycosides.
Resistance to an antibiotic class was defined as resistance to all
drugs representative of that class in our panel. PDR A. bau-
mannii was defined as resistance to all five antibiotic classes and
resistance to tetracycline and trimethoprim-sulfamethoxazole.
Statistical Analyses
All statistical analyses were performed on SAS R© 9.3 software.
The continuous outcome of mean 560 nm absorbance between
comparison groups were tested using student’s t-test. To deter-
mine whether frequency counts are distributed the same across
different populations of A. baumannii, a chi-square test of homo-
geneity was used. Significance threshold was set at α = 0.05.
Results
Descriptive Epidemiology
A. baumannii was isolated from 290 patients receiving acute care
in the DMC healthcare system between January 2010 and May
2011 (17 month time period). If multiple isolates were obtained
from an individual, one was randomly selected for inclusion. The
majority of isolates (88%) were taken from three hospitals. The
remaining 12% were isolated from 4 other hospitals. A. bauman-
nii found from any anatomic site were included. For analysis,
the anatomic sites of isolation were categorized by anatomical
system. For example, sputum and bronchial alveolar lavage spec-
imens were defined as respiratory. Respiratory (39%), urinary
(20%), wound (17%), and blood (14%) were the source for 90%
of isolates. The remaining A. baumannii isolates were found in
tissue, peritoneal/cerebral-spinal fluids, eye/ear/skin swabs, and
specimens indicated as “other.” The mean age of the study cohort
was 57 years with a standard deviation of 21 years. The number
of male patients was 155 (53%). Of the 290 patients, 72% were
African American, 16%white, 1%Hispanic, and<1%Asian; 11%
patients had undocumented races or were indicated as “other.” A
comprehensive breakdown of patient demographics and isolate
descriptives by endemicity is shown in Table 1.
REP Clusters
There were a total of 98 REP genotypes identified amongst the
290 A. baumannii isolates tested, 5 of which were observed at
least 10 times in the collection. REP-1 and REP-2 were observed
in 6/7 hospitals; REP-3 and REP-4 were observed in 4/7 hos-
pitals, and REP-5 was observed in 3/7 hospitals. One hospi-
tal, Children’s Hospital, had no endemic REP-type isolations.
REP-1 and REP-2 occurred at least 10 times in a single hospi-
tal. One genotype, REP-1, accounted for 33% of isolates (n = 96).
Figure 1 shows a sample gel image (Figure 1A), and associated
cladogram (Figure 1B). The remaining four predominant REP
genotypes were 9% (REP-2), 6% (REP-3), 6% (REP-4), and 5%
(REP-5) of the total (Figures 1B, 2D). The next highest REP
genotype occurred among only 2% of the isolates. This genotype
together with the remainder of the REP-genotypes was consid-
ered to be sporadic. REP-1 through REP-5 will be referred to
as endemic isolates in the remainder of the manuscript. Days
between isolation of the same REP-type within a single hospi-
tal ranged from 0 to 203 days (average = 29 days). REP-1 pre-
dominated: at-least one isolate was identified in every month
of surveillance. REP-types were associated with specific facilities
(chi-square p = 0.01). Seventy-four of 96 (77%) REP-1 isolates
were isolated from just two hospitals. A third hospital had only
sporadic REP-types. Endemic isolates were not associated with
anatomic site of isolation (p = 0.96).
Presence of bap and blaOXA-23 Genes
243 (84%) isolates in the study possessed the A. baumannii bap
gene and 105 (36%) possessed the blaOXA-23 gene. Of the 243
that had bap, 138 possessed it alone and the other 105 had
the combination of bap and blaOXA-23. No isolates possessed
blaOXA-23 independently of bap. Endemic isolates were more
likely than sporadic to carry blaOXA-23 genes and bap genes and
these differences are statistically significant (Table 1).
Antibiotic Resistance
MIC determinations were available for all but 6 endemic and
6 sporadic strains. These 12 isolates did not culture adequately
for MicroScan tests at Henry Ford Hospital. Endemic isolates
were more likely to be resistant (p < 0.05) to each antibi-
otic tested except for amikacin and tigecycline (Table 2), and
more likely to be characterized as MDR than sporadic isolates
(p < 0.05). When observing antibiotic resistance patterns by
bap and blaOXA-23 genes, isolates with bap, but not blaOXA-23 pos-
sessed the least number of resistances to the panel of antibiotics
(including A. baumannii isolates that did not contain either bap
or blaOXA-23). Isolates with blaOXA-23 possessed the most number
of resistances to the panel of antibiotics. One isolate was resistant
to all 17 antibiotics in the panel. This isolate belonged to REP-3,
an endemic REP genotype we observed 16 times.
Biofilm Quantification
Biofilm development as determined by biofilm biomass was mea-
sured by optical absorbance (560 nm) for all 290 isolates using
crystal violet. On hydrophobic polystyrene surfaces the mean
absorbance was 1.2 with a standard deviation of 0.7 and a range
from <0.1 to 2.6. For relatively hydrophilic glass surfaces, the
mean absorbance was 0.9 with a standard deviation of 0.5 and
a range from <0.1 to 3.0 (Supplementary Table 1). Irrespec-
tive of whether an isolate was grown on glass or polystyrene,
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TABLE 1 | Comparison of various patient demographic factors and isolate descriptives of 121 sporadic A. baumannii and 169 endemic A. baumanniiab
isolated at the Detroit Medical Center between Jan. 2010–May 2011.
A. baumannii isolate classification Sporadic (N = 121) Endemic (N = 169) p-valuec
REP-1 REP-2 REP-3 REP-4 REP-5
Count 121 96 27 16 16 14
Race Black 82 (68%) 72 (75%) 22 (81%) 13 (81%) 12 (75%) 8 (57%) 0.17
White 19 (16%) 14 (15%) 3 (11%) 2 (13%) 3 (19%) 4 (29%) 0.94
Other 15 (12%) 10 (10%) 2 (8%) 1 (6%) 1 (6%) 2 (14%) 0.43
Hispanic 4 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Asian 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Gender Male 61 (50%) 47 (49%) 16 (59%) 13 (81%) 9 (56%) 9 (64%) 0.38
Facility Sinai Grace 41 (34%) 44 (46%) 13 (48%) 6 (38%) 8 (50%) 5 (36%) 0.058
Detroit Receiving 27 (22%) 30 (31%) 10 (37%) 5 (31%) 4 (25%) 5 (36%) 0.071
Harper-Hutzel 29 (24%) 17 (18%) 1 (4%) 3 (19%) 2 (13%) 4 (29%) 0.089
Children’s Hospital 15 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Huron Valley 3 (2%) 1 (1%) 1 (4%) 0 (0%) 2 (13%) 0 (0%) N/Ad
Karmanos Cancer 3 (2%) 1 (1%) 1 (4%) 2 (13%) 0 (0%) 0 (0%) N/Ad
Rehab. Institute 3 (2%) 3 (3%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Site of Respiratory 43 (36%) 39 (41%) 14 (52%) 4 (25%) 8 (50%) 5 (36%) 0.31
Isolation Urine 26 (21%) 20 (21%) 3 (11%) 5 (31%) 2 (13%) 2 (14%) 0.59
Wound 20 (17%) 15 (16%) 4 (15%) 4 (25%) 3 (19%) 2 (14%) 0.99
Blood 18 (15%) 12 (13%) 3 (11%) 1 (6%) 2 (13%) 2 (14%) 0.65
Tissue 8 (7%) 5 (5%) 1 (4%) 0 (0%) 1 (6%) 1 (6%) 0.49
Fluid 3 (2%) 2 (2%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Other 0 (0%) 2 (2%) 1 (4%) 1 (6%) 0 (0%) 0 (0%) N/Ad
Eye 2 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) N/Ad
Ear 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Skin 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/Ad
Isolate blaOXA-23 20 (17%) 58 (60%) 16 (59%) 7 (44%) 2 (13%) 2 (14%) <0.01
Biomarker bap 93 (77%) 91 (95%) 25 (93%) 15 (94%) 14 (88%) 5 (36%) <0.01
a Endemic A. baumannii defined as occurrence of identical REP-PCR patterns in counts greater than or equal to 10 during the course of surveillance. All other REP-types are considered
sporadic.
b Percentages are calculated with column total in denominator and may not add up perfectly to 100% due to rounding to the nearest whole percent.
c p-value is calculated between the endemic (n = 169) group and sporadic (n = 121) group.
d Chi-square a weak and non-applicable test due to expected value count <5.
a similar trend was observed whereby the highest and lowest
biofilm-formers on one surface-type displayed the same biofilm-
forming abilities on the other surface-type (Supplemental
Figure 1).
Biofilm biomass was significantly greater among endemic and
sporadic isolates carrying bap (Figures 2A,B), but was not asso-
ciated with MDR (Figure 2C). Endemic REP types 1–4 generated
biofilms of greater average biomass than the average biomass
produced by the sporadic isolates, whereas REP type 5 aver-
aged biofilms of lower biomass (Figure 2D). This result is also
reflected in the prevalence of the bap gene amongst the REP types.
Prevalence of bap in REP types 1–4 range from 88% to 95%; the
prevalence of bap in REP type 5 is 36%. Overall, endemic isolates
averaged biofilms of greater biomass than sporadic isolates on
both polystyrene (hydrophobic) surfaces (1.3 vs. 1.1, p < 0.05)
and glass (relatively hydrophilic) surfaces (1.0 vs. 0.8, p < 0.05).
Microscopic visualization of biofilms of three randomly
selected A. baumannii isolates that contained the bap gene, bap
and blaOXA-23 genes, or neither of these genes (remembering
that no blaOXA-23 alone were detected in our study) showed that
there was a clear relationship between the results from the crys-
tal violet assay and the amount of observed biomass (Figure 3).
Strains containing bap or bap and blaOXA-23 were thicker, covered
greater surface area, and possessed three-dimensional tower-
like structures containing multiple cells compared to strains
without bap and blaOXA-23, which formed scant biofilms with
most of the biofilm cells being alone or in clusters of 2–5
cells.
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FIGURE 1 | Sample gel image of the fingerprint generated from
REP-PCR of Acinetobacter baumannii isolates collected at a single
hospital in the Detroit Medical Center system organized by date of
isolation. Panel (A) shows lanes 7, 8, 14, 15, 23, 24, 28, 30, and 32
represent REP-1, the most diffusive clone identified. REP-2 and REP-3 are
also present on this gel shown by lanes 1, 10, 13, and 22, and lanes 9, 25,
26, and 29, respectively. REP-4 and REP-5 were not run in this sample gel,
but are cropped in for comparison. REP-4 is marked Lanes A–D and REP-5 is
marked Lanes E–H. Panel (B) shows a phylogenetic tree of sample gel using
neighbor joining method is also shown. Five clusters are evident and were
classified as REP clones. The clusters are indicated by grayed background.
The others were designated sporadic isolations and are indicated by a white
background. Lettered lanes were added to the analysis to include REP-4 and
REP-5 and were derived from separate gels from numbered lanes.
Discussion
In this study of 290 A. baumannii isolates conducted using clini-
cal surveillance in a large healthcare system, endemic healthcare
isolates were more likely than sporadic isolates to be antibiotic
resistant, carry the bap and blaOXA-23 genes, and have enhanced
biofilm-forming abilities. These findings are exciting as this
suggests that the ability to form biofilms may, independent of
antibiotic resistance, enhanceA. baumannii’s ability to persist and
recirculate within a healthcare system.
We found 5 REP-PCR types that occurred more than 10 times
amongst unique patients during the 17 months of surveillance.
Furthermore, for 16 of the 17 study months, multiple REP clus-
ters were isolated. This suggests that rather than an outbreak
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FIGURE 2 | Biofilm quantification by various groupings of the
population of 290 clinical A. baumannii isolates collected using
active surveillance at the Detroit Medical Center between Jan.
2010-May 2011. The referent boxplot for each panel is the panel
on the far left. A ∗ indicates significant difference in mean 560 nm
absorbance from referent boxplot (p < 0.05). (A) Breaks down the
population of isolates by genetic biomarker, (B) by clonality and
MDR phenotype, (C) by REP-type, and (D) by clonality and genetic
biomarker. 95% confidence limits are also included to the right side
of each box plot.
characterized by a rapid dissemination of a single clone, multi-
ple REP types were observed to be recirculating within the DMC.
When considering all endemic isolates vs. all sporadic isolates,
52% of all the endemic REP-clones were MDR (vs. 32% for the
sporadics), 50% carried bap and blaOXA-23 (vs. 17% for the spo-
radics), and the endemic isolates formed statistically significant
denser biofilms than their sporadic counterparts (average of 1.3
vs. 1.1, respectively). These numbers further support our hypoth-
esis that antibiotic resistancemarkers and biofilm-forming ability
are associated with persistence.
Previous studies have estimated the prevalence of bap and
blaOXA-23 but, unlike this study, most have not associated these
genes with antibiotic resistance or biofilm characteristics. A
recent study in Australia demonstrated that among 24 isolates
of A. baumannii from a single outbreak, 22 (92%) possessed
the bap gene (Goh et al., 2013). Among our surveillance iso-
lates, bap was also common, occurring in 84% of the isolates.
The biomarker blaOXA-23 was present in 36% of our surveil-
lance isolates, occurred exclusively in the presence of bap,
and was strongly associated with endemic REP-PCR types and
multi-drug resistance. Furthermore, 76% of blaOXA-23 positive
isolates were multi-drug resistant and 7% were pan-drug resis-
tant. The percentages are difficult to compare with other studies
since most previous studies selected a subset of carbapenem-
resistant A. baumannii to test for presence of blaOXA-23 rather
than an entire clinical population. For example, in Brazil, 13/500
carbapenem-resistant A. baumannii isolated from 16 hospitals
between 2004 and 2008 were selected for molecular analyses and
all 13 isolates were found to be OXA-23 producers (Martins et al.,
2009). The blaOXA-23 gene has been detected in MDR outbreaks
worldwide (Peleg et al., 2008), but limited studies have implicated
OXA-23 producing A. baumannii outbreaks in North American
hospitals.
Classifications of multi-drug and pan-drug resistance can be
vague. This is because the classifications can be based on dif-
ferent combinations of the drug classes commonly used to treat
A. baumannii. These drugs include cephalosporins, beta-lactam
and beta-lactamase inhibitors, carbapenems, fluoroquinolones,
aminoglycosides, tetracyclines, and polymyxins (Doi et al., 2015).
For the work presented here, surveillance spanned 17 months.
This gives us a sustained longitudinal overview of the loss or
persistence of antibiotic resistances expressed by the A. bauman-
nii population present in the DMC. Of possible concern is that
70–78% of the isolates were resistant to the 4 cephalosporins
and the 2 fluoroquinolones in our panel over the 17 month
period (Table 2). Carbapenems, often considered the last resort
antibiotics for A. baumannii (Smith et al., 2013), were ineffec-
tive against 40–52% of our isolates. Beta-lactams/beta-lactamase
inhibitor combinations and aminoglycosides retained moder-
ate efficacy with 34–58% inefficacy against our collection. The
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TABLE 2 | Count and percent of A. baumannii isolates resistant to selected antibiotics by genetic biomarker and REP-Genotype.
Genetic biomarker REP-Genotype All isolations
Group Neither bap bap alone Both bap Sporadic Endemic Total study
nor blaOXA-23 and blaOXA-23 population
Count 47 131 100 115 163 278
Cephalosporins Ceftriaxone 72 58 91∗÷ 60 81∗ 72
Ceftazidime 72 56 91∗÷ 58 81∗ 72
Cefotaxime 79 60∗ 92∗÷ 62 84∗ 75
Cefepime 74 52∗ 91∗÷ 59 77∗ 70
All 4 cephalosporins 66 45∗ 83∗÷ 50 71∗ 62
Carbapenems Imipenem 40 13∗ 75∗÷ 30 47∗ 40
Meropenem 60 27∗ 82∗÷ 43 58∗ 52
All 2 carbapenems 40 12∗ 75∗÷ 29 47∗ 40
B-lactam + inhibitor Ampicillin + sulbactam 40 21∗ 52÷ 22 45∗ 36
Piperacillin + tazobactam 70 34∗ 84÷ 47 66∗ 58
Ticarcillin + clavulanate 51 26∗ 84∗÷ 40 59∗ 51
All 3 β-lactams + inhibitors 32 9∗ 43÷ 16 32∗ 25
Fluoroquinolones Ciprofloxacin 77 65 96∗÷ 63 88∗ 78
Levofloxacin 70 59 87∗÷ 55 82∗ 71
All 2 fluoroquinolones 70 58 87∗÷ 54 82∗ 71
Aminoglycosides Amikacin 47 22∗ 74∗÷ 38 50 45
Gentamicin 47 50 72∗÷ 47 65∗ 58
Tobramycin 23 25 50∗÷ 23 41∗ 34
All 3 Aminoglycosides 13 7 45∗÷ 13 28∗ 22
Other antibiotics Tetracycline 40 29 49÷ 28 45∗ 38
Trimethoprim + sulfamethoxazole 66 56 92∗÷ 57 80∗ 71
Tigecyclineb 11 5 10 6 9 8
Phenotype Multi-drug resistantc 47 18∗ 76∗÷ 32 52∗ 44
Pan-drug resistantd 0 0 7 1 4 3
Two-hundred and seventy-eight phenotyped clinical A. baumannii isolates collected using active surveillance at the Detroit Medical Center between Jan. 2010–May 2011ae.
aColumns within genetic biomarker and REP-genotype are mutually exclusive, but columns between genetic biomarker and REP-genotype are not.
bResistance determined using BSAC breakpoint.
cMulti-drug resistance defined as resistance to all antibiotic representatives in at least three of the five following classes: cephalosporins, carbapenems, β-lactam + inhibitor combina-
tions, fluoroquinolones, and aminoglycosides.
dPan-drug resistance defined as resistance to all antibiotic representatives in all five of the following classes: cephalosporins, carbapenems, β-lactam + inhibitor combinations, fluoro-
quinolones, and aminoglycosides, in addition to resistance to tetracycline and trimethoprim-sulfamethoxazole.
e Isolations include invasive and non-invasive A. baumannii.
fResistance was not available for 12 isolates. See text.
∗Difference in proportion significant at the 5% level from the baseline group. Baseline for genetic biomarker is neither bap nor OXA-23 and baseline for REP-genotype is sporadic.
÷Difference in proportion significant at the 5% level between bap alone group and bap + OXA-23 group.
high prevalence of multi-drug resistance has significant public
health implications. In some instances, there are limited treat-
ment options for symptomatic patients. Asymptomatic patients
carrying A. baumannii may also serve as a reservoir and aid in
spread to other facilities, which may ultimately prolong the cir-
culation of MDR A. baumannii within a facility (Marchaim et al.,
2007).
Our data suggest that an increased ability to form biofilms
does not confer increased resistance to antibiotics, after
controlling for whether isolates were endemic or sporadic
(Figure 2C). The absence of an interacting effect is at first-
glance surprising given that bacteria in biofilms have altered
growth properties, which reduces antimicrobial susceptibility,
and many antimicrobials can undergo reaction diffusion lim-
itation when penetrating biofilms (i.e., biofilms of increasing
thickness retard access) (Manchanda et al., 2010). However, our
approach to test antimicrobial susceptibility was based upon the
MicroScan broth microdilution test that relies upon planktonic
growth. Therefore, the ability to detect a relationship between
biofilm formation and antimicrobial resistance is based upon
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FIGURE 3 | Biofilm quantification process of four A. baumannii
isolates using crystal violet staining, measurement from a 96-well
plate reader, and visualization using confocal laser scanning
microscopy. (A) Shows DMC0256, a representative sample bap alone
isolate. (B) Shows DMC0420 with both blaOXA-23 and bap. (C) Shows
DMC0551, a representative non-bap isolate. A top view, side view, and
angled view of the biofilm from each isolate is shown to illustrate biomass,
thickness, and confluence differences between the isolates.
an environmentally unrepresentative situation. Growth in plank-
tonic phase, as opposed to the preferred biofilm growth, could
be the reason why isolates carrying bap alone were more sus-
ceptible to all antibiotics listed in our panel than those without
bap and those carrying the combination of bap and blaOXA-23
(Table 2). Whether this is a causal association or one that is due
to the Bap protein enhancing antimicrobial tolerance in biofilms
but reducing resistance in planktonic populations remains to
be determined. We found no other studies in the literature for
comparison.
When considering our approach to evaluate biofilm
formation, the crystal violet staining technique is a tried-
and-tested technique capable of accurately estimating biofilm
formation especially when large panels of isolates are being
evaluated (Van Houdt et al., 2004; O’Toole, 2011; Rao et al., 2011;
Coffey and Anderson, 2014). We found that the variation of
measurements within an isolate were very consistent amongst the
triplicate measurements (Figure 3), but between isolates ranged
considerably. This is shown by the large standard deviations
and wide range of absorbance values in Supplementary Table
1. When considering the variation in biofilm forming ability
between the different strains, it is very likely that bap is one
in a suite of genes that can enhance biofilm development. For
example, A. baumannii pili is integral for initial attachment to
surfaces prior to biofilm maturation (Nait Chabane et al., 2014).
Similarly, the products of other genes may change the proper-
ties of A. baumannii cells, such as whole-cell hydrophobicity
and altered bacterial cell-cell signaling that can retard biofilm
forming ability (Niu et al., 2008; Pour et al., 2011; Kempf et al.,
2012). This may explain why, for example, we observed some
bap isolates that were poor at forming biofilms and vice-versa.
Some may question the clinical relevance of the observed sta-
tistically significant differences in biofilm forming ability between
endemic and sporadic isolates as the absolute difference in mea-
sures is small. However, given that optical density measure-
ments above approximately 0.5 do not linearly correlate with
biomass (poor correspondence with Beer’s law) (Lee and Lim,
1980; Fuchs and Kroger, 1999), it is likely that the actual differ-
ence in biomass between the average optical densities is much
larger than conveyed by the biofilm assay. Further, we observed
the same significant differences in biofilm biomass between
endemic and sporadic isolates on two contrastingly different
surfaces (hydrophobic polystyrene and relatively hydrophilic
glass).
In summary, the work presented here indicates that A. bau-
mannii isolates endemic to hospitals are more likely than
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sporadic isolates to be resistant to antibiotics, carry bap and
blaOXA-23, and form biofilms of greater biomass in vitro. This
suggests that specific environmental pressures select for char-
acteristics, such as biofilm formation, that enhance survival of
A. baumannii in healthcare environments. Taken in context with
other studies, our work highlights the importance of antimi-
crobial stewardship (Fishman, 2006; Garg and Guez, 2011) and
the potential application of novel “anti-biofilm” technologies
(Simões et al., 2010; Thallinger et al., 2013) to control A. bau-
mannii in hospital environments.
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